Last reviewed · How we verify
NNC0142-0002
At a glance
| Generic name | NNC0142-0002 |
|---|---|
| Sponsor | Janssen Research & Development, LLC |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- First-in-man Trial of NNC0142-0002 in Patients With Rheumatoid Arthritis (PHASE1)
- Efficacy of NNC0142-0002 in Subjects With Rheumatoid Arthritis (RA) (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- NNC0142-0002 CI brief — competitive landscape report
- NNC0142-0002 updates RSS · CI watch RSS
- Janssen Research & Development, LLC portfolio CI